Evidence map›Paper›PMID 41454694›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Low YTHDC1 Expression Upregulates FSCN1 to Promote Nuclear F-Actin Formation and Facilitate Double-strand DNA Breaks Repair in TMZ-Resistant Glioblastoma.

Minglong Yang, Wanxiang Niu, Yuanfei Wang, Peng Chen, Maolin Mu, Xiaoming Zhang, Ben Xu, Shanshan Hu, Chaoshi Niu, Pengfei Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Minglong YangDepartment of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Wanxiang NiuDepartment of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Yuanfei WangDepartment of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Peng ChenDepartment of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Maolin MuDepartment of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Xiaoming ZhangDepartment of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Ben XuDepartment of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Shanshan HuDepartment of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Chaoshi NiuDepartment of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Pengfei WuDepartment of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.ORCID https://orcid.org/0000-0001-7621-5970

Funding

2022 Anhui Province Postdoctoral Researchers' Scientific Research Activity Funding Project 2022B580Central Universities WK9110000145China Postdoctoral Science Foundation 2022TQ0326China Postdoctoral Science Foundation 2023M733391Guiding Local Science and Technology Development by the Central Government 2019b07030001National Natural Science Foundation of China 82202868National Natural Science Foundation of China 82273281National Natural Science Foundation of China 82573367Natural Science Foundation of Anhui Province 2208085QH251Open Project of Anhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment KFKT202401
6 · The paper itself

Abstract

Glioblastoma (GBM) is an aggressive and recurrent malignancy with a poor prognosis. Although temozolomide (TMZ) is a cornerstone of GBM treatment, its efficacy is often compromised by inherent or acquired resistance, underscoring the urgent need to uncover molecular mechanisms, discover new therapeutic targets, and develop innovative treatment strategies. In this study, we found an increased formation of filamentous actin (F-actin) within the nuclei of TMZ-resistant GBM cells. We also showed that overexpression of FSCN1 in TMZ-resistant GBM cells promotes F-actin formation and facilitates the repair of DNA double-strand breaks (DSBs). Further investigation revealed a marked decrease in the expression of YTHDC1 in TMZ-resistant GBM cells, which regulates FSCN1 through m6A modification. Additionally, FSCN1 activates the CDC42/N-WASP/Arp2/3 signaling pathway by recruiting FGD1 to activate CDC42

Indexed as

ActinsBrain NeoplasmsDNA RepairDrug Resistance, NeoplasmGlioblastomaMicrofilament ProteinsTemozolomideAnimalsCarrier ProteinsCell Line, TumorDNA Breaks, Double-StrandedGene Expression Regulation, NeoplasticHumansMiceMice, NudeUp-RegulationActinsCarrier ProteinsFSCN1 protein, humanMicrofilament ProteinsTemozolomideclinical therapyDSBs repairfilamentous actin formationglioblastomatemozolomide resistance

Identifiers

PMID41454694
PMCPMC12955858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.